Actions and interactions of antithrombin and heparin

Jan 1, 1980·Research in Experimental Medicine. Zeitschrift Für Die Gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie·W CullmannP Jürgens

Nephrotic syndrome: a platelet hyperaggregability state

Jul 1, 1985·Veterinary Research Communications·A Rasedee, B F Feldman

Antithrombin III (AT III) Padua2: a "new" congenital abnormality with defective heparin co-factor activities but no thrombotic disease

Aug 1, 1983·Blut·A GirolamiG Boeri

Effect of heparin and prostacyclin-heparin infusion on blood coagulation in haemodialysed patients

Jan 1, 1991·International Urology and Nephrology·M KuźniewskiJ Lisiewicz

Chronic adult renal vein thrombosis: two unusual cases and a review of the literature

Jan 1, 1991·International Urology and Nephrology·D TheodorescuJ Connolly

Five novel and four recurrent point mutations in the antithrombin gene causing venous thrombosis

Aug 5, 2003·International Journal of Hematology·Keiko NagaizumiKatsuyuki Fukutake

Excessive requirement for heparin during cardiac surgery

May 1, 1981·Canadian Anaesthetists' Society Journal·F ChungJ Watt

Anticoagulants in anaesthesia

Nov 1, 1987·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·P J Stow, F A Burrows

Chronic pulmonary thromboendarterectomy complicated by antithrombin III deficiency and antiphospholipid syndrome

Jan 13, 1999·The Japanese Journal of Thoracic and Cardiovascular Surgery : Official Publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai Zasshi·M AndoS Kitamura

Small bite, large impact-saliva and salivary molecules in the medicinal leech, Hirudo medicinalis.

Nov 10, 2011·Die Naturwissenschaften·Jan-Peter Hildebrandt, Sarah Lemke

Antithrombin level and circuit thrombosis during hemofiltration after cardiopulmonary bypass.

Jun 26, 2008·Intensive Care Medicine·H LanquetotL Macchi

Superior mesenteric and portal vein thrombosis caused by congenital antithrombin III deficiency: report of a case

Mar 28, 2007·Surgery Today·Kotaro ShibaharaHitoshi Kohno

The increase in human antithrombin III tryptophan fluorescence produced by heparin

May 24, 1978·Biochimica Et Biophysica Acta·R Einarsson

Protein C and protein S clinical perspectives

Nov 30, 1987·Clinica Chimica Acta; International Journal of Clinical Chemistry·C M Kessler, D K Strickland

Identification of the second alpha-2-antiprotease of equine serum as antithrombin III

Jan 1, 1983·The International Journal of Biochemistry·A PellegriniR von Fellenberg

Hematologic disorders associated with ischemic stroke

Sep 1, 1996·Journal of the Neurological Sciences·T Tatlisumak, M Fisher

Prophylaxis of thrombosis in antithrombin III-deficient women during pregnancy and delivery

Oct 1, 1984·European Journal of Obstetrics, Gynecology, and Reproductive Biology·J J MichielsH H van Vliet

Heparin like activity of albumin.

Jan 1, 1979·Thrombosis Research·K A Jøorgensen, E Stoffersen

Antithrombin III in rat hepatocytes

Oct 1, 1982·Thrombosis Research·M LéonF Jaubert

Antithrombin III in renal transplant recipients

May 1, 1985·Thrombosis Research·K T WooC H Lim

A functional abnormal antithrombin III (AT III) deficiency: AT III Charleville

Sep 1, 1985·Thrombosis Research·M AiachM A Gelas

Antithrombin III deficiency as a risk factor for catheter-related central vein thrombosis in cancer patients

Apr 15, 1995·Thrombosis Research·M De CiccoV Testa

Variable influence of heparin and contrast agents on platelet function as assessed by the in vitro bleeding time

Aug 1, 1996·Thrombosis Research·L G MeltonD A Gabriel

A comparison of two anesthetic techniques for the study of rat skeletal muscle high-energy phosphates in vivo using 31P-NMR.

Mar 17, 1988·Biochimica Et Biophysica Acta·S F LoyL D Segel

Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction

Jan 1, 1995·Journal of the American College of Cardiology·P A MerliniR D Rosenberg

Homocysteine and coronary atherosclerosis

Mar 1, 1996·Journal of the American College of Cardiology·E L MayerK Robinson

Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease

Aug 15, 2000·European Journal of Pharmacology·A PothulaD Atar

Anticoagulant and antithrombin effects of intimatan, a heparin cofactor II agonist

Sep 7, 2000·Thrombosis Research·M R Buchanan, S J Brister

Thrombin inhibition by HCII in the presence of elastase-cleaved HCII and thrombin-HCII complex

Jan 11, 2001·Thrombosis Research·H MaekawaD M Tollefsen

Relationship between fibrinogen protein and fibrinogen function in postmyocardial infarction patients

Jan 5, 2002·Thrombosis Research·E RéganonJ Aznar

Side-effects of rinsing fluids on the rat femoral artery. A histological and electron microscopic study

Sep 30, 1998·The Journal of Hand Surgery : Journal of the British Society for Surgery of the Hand·O DelaereD Boomker

Molecular genetics of antithrombin deficiency

Jun 1, 1996·Blood Reviews·D A LaneS L Thein

Review of hypercoagulability syndromes: what the interventionalist needs to know

May 1, 1991·Journal of Vascular and Interventional Radiology : JVIR·B A Perler

Scientific considerations in the review and approval of generic enoxaparin in the United States

Mar 9, 2013·Nature Biotechnology·Sau LeeJanet Woodcock

Protein therapeutics: a summary and pharmacological classification.

Dec 22, 2007·Nature Reviews. Drug Discovery·Benjamin LeaderDavid E Golan

Letter: DIC-fibrinolysis with low antithrombin-heparin cofactor

Apr 10, 1975·The New England Journal of Medicine·K EureniusT D Rossi

Prevention of recurrent venous thrombosis: warfarin versus heparin

Mar 27, 1980·The New England Journal of Medicine·W M Miller, C A Medbery

Molecular heterogeneity of inherited antithrombin III deficiency

Jun 30, 1983·The New England Journal of Medicine·E V ProchownikS H Orkin

Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 51-1984. A 45-year-old man with abdominal pain and abnormal CT scan

Dec 20, 1984·The New England Journal of Medicine

In vitro and in vivo correlation of clotting protease activity: effect of heparin

Jul 1, 1977·Proceedings of the National Academy of Sciences of the United States of America·S N GitelS Wessler

❮ Previous

Next ❯

Related Concepts

Related Feeds

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Actions and interactions of antithrombin and heparin

Abstract

References

Comparison of progressive antithrombin activity and the concentration of three thrombin inhibitors in human plasma

The first component of the kinin-forming system in human and rabbit plasma. Its relationship to clotting factor XII (Hageman Factor)

Inhibition of plasmin activity by alpha-2-macroglobulin

Heparan sulfates of cultured cells. I. Membrane-associated and cell-sap species in Chinese hamster cells

Sulfated mucopolysaccharide synthesis and secretion in endothelial cell cultures

Activation of Hageman factor by collagen

Role for a 2 -macroglobulin in haemostatic balance

Anticoagulant action of heparin

Measurement of fibrinopeptide A in human blood

Heparin action

Antithrombin 3, antifactor Xa and heparin

Highly purified antithrombin 3 with heparin cofactor activity prepared by disc electrophoresis

Homologies between thrombin and other serine proteinases

Structure of N-terminal fragments of fibrinogen and specificity of thrombin

An autoradiographic study on the uptake of S35-labelled sodium sulphate in the mast cells

Quantitative aspects of antithrombin and heparin in plasma

NEUTRALIZATION OF AUTOPROTHROMBIN C ACTIVITY WITH ANTITHROMBIN

WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING

Studies on the antithrombin and heparin cofactor activities of a fraction adsorbed from plasma by aluminum hydroxide

Citations

Molecular genetics of human antithrombin deficiency

Hereditary antithrombin III deficiency and thromboembolic disease

Low molecular weight heparins: an emerging new class of glycosaminoglycan antithrombotics.

Pharmacodynamics, clinical indications, and adverse effects of heparin.

Heparinized styrene-butadiene-styrene elastomers

Bacteria/blood/material interactions. I. Injected and preseeded slime-forming Staphylococcus epidermidis in flowing blood with biomaterials

Human pharmacology of a low-molecular-weight heparin (Alfa-LMWH): an update

Use of anticoagulants in replantation and elective microsurgery

Influence of topical heparin on stasis-induced thrombosis of microvascular anastomoses

Antithrombin III substitution affects survival rate in a murine malaria model

Coagulation parameters and heparin levels in open-heart surgery